SYSTEMATIC REVIEW AND META-ANALYSIS OF BRIAKINUMAB, A FULLY HUMAN INTERLEUKIN 12/23 MONOCLONAL ANTIBODY, FOR THE TREATMENT OF MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS

被引：0
|
作者：
Vsn, M.
Mothe, R. K.
Hyderboini, R. K.
Likhar, N.
Ganji, K.
Singuru, S.
Dang, A.
机构：
[1] MarksMan Healthcare Solut LLP, Hlth Econ & Outcomes Res HEOR, Navi Mumbai, India
[2] RWE, Navi Mumbai, India
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.494
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS5
引用
收藏
页码：A123 / A123
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis
    Kimball, Alexa B.
    Gordon, Kenneth B.
    Langley, Richard G.
    Menter, Alan
    Chartash, Elliot K.
    Valdes, Joaquin
    ARCHIVES OF DERMATOLOGY, 2008, 144 (02) : 200 - 207
  • [2] Treatment of psoriasis with interleukin-12/23 monoclonal antibody: a systematic review
    Wu, Yan
    Chen, Jing
    Li, Yuan-Hong
    Ma, Guo-Zhang
    Chen, John Z. S.
    Gao, Xing-Hua
    Chen, Hong-Duo
    EUROPEAN JOURNAL OF DERMATOLOGY, 2012, 22 (01) : 72 - 82
  • [3] Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: A meta-analysis
    Tan, Ji Ying
    Li, Shaohong
    Yang, Kehu
    Ma, Bin
    Chen, Wanqiang
    Zha, Chengxi
    Zhang, Junying
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2011, 22 (06) : 323 - 336
  • [4] Systematic Review of Interleukin-12, Interleukin-17, and Interleukin-23 Pathway Inhibitors for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis: Ustekinumab, Briakinumab, Tildrakizumab, Guselkumab, Secukinumab, Ixekizumab, and Brodalumab
    Tausend, William
    Downing, Christopher
    Tyring, Stephen
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2014, 18 (03) : 156 - 169
  • [5] A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
    Krueger, Gerald G.
    Langley, Richard G.
    Leonardi, Craig
    Yeilding, Newman
    Guzzo, Cynthia
    Wang, Yuhua
    Dooley, Lisa T.
    Lebwohl, Mark
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (06): : 580 - 592
  • [6] Interleukin 12/23 monoclonal antibody in the treatment of psoriasis
    Heller, Marissa
    JOURNAL OF DRUGS IN DERMATOLOGY, 2008, 7 (04) : 417 - 417
  • [7] Guselkumab: human monoclonal antibody against interleukin-23 for moderate to severe psoriasis
    Paton, D. M.
    DRUGS OF TODAY, 2018, 54 (03) : 199 - 207
  • [8] Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis
    Bansback, Nick
    Sizto, Sonia
    Sun, Huiying
    Feldman, Steven
    Willian, Mary Kaye
    Anis, Aslam
    DERMATOLOGY, 2009, 219 (03) : 209 - 218
  • [9] Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis
    Erichsen, C. Y.
    Jensen, P.
    Kofoed, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (01) : 30 - 38
  • [10] Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis
    Attia Attia
    Abdelrahman Ibrahim Abushouk
    Hussien Ahmed
    Mohamed Gadelkarim
    Ahmed Elgebaly
    Zeinab Hassan
    Mohamed M. Abdel-Daim
    Ahmed Negida
    Clinical Drug Investigation, 2017, 37 : 439 - 451
12345